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Abstract
Pregnant substance users can benefit significantly from substance abuse treatment but treatment
retention can be challenging. Two hundred pregnant substance users entering outpatient substance
abuse treatment at 1 of 4 treatment programs were randomized to receive either 3 individual sessions
of Motivational Enhancement Therapy for pregnant substance users (MET-PS) or the first 3
individual sessions normally provided by the program. All participants were encouraged to
participate in all other treatment offered by the program. Outcome measures included treatment
utilization according to clinic records, qualitative urine toxicology measures, and self-report of
substance use. One hundred and sixty two participants (i.e., 81%) completed the 1 month active
phase. Participants attended 62% of scheduled treatment on average and reported decreased substance
use during the first month of treatment, with no differences between MET-PS and treatment as usual
participants. There was some evidence that the efficacy of MET-PS varied between sites and that
MET-PS might be more beneficial than TAU in decreasing substance use in minority participants.
These results suggest that MET-PS is not more effective than treatment as usual for pregnant
substance users in general but that there might be particular subgroups or treatment programs for
which MET-PS might be more or less effective than treatment as usual.
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1. Introduction
During pregnancy, an estimated 4% of women use illicit substances, 4% binge drink, and 18%
smoke cigarettes, the associated prenatal, neonatal, and postnatal complications of which
represent a leading preventable cause of mental and physical problems in children (SAMHSA,
2005). Past research suggests that substance abuse treatment is effective in decreasing
substance use and improving birth outcomes for pregnant women who attend treatment
(McMurtrie et al., 1999; Jones et al., 2002) but that retaining pregnant women in treatment can
be difficult (Haller et al., 1997); hence increasing treatment utilization has been identified as
an important goal for programs treating pregnant substance users (Howard and Beckwith,
1996). Past research suggests that treatment retention can be improved by providing case
management (Jones et al., 2004) or housing (Haller et al., 1997) to help pregnant women
stabilize their living situations and by removing external barriers to treatment, for example, by
providing transportation and child care (Weisdorf et al., 1999) but that retention is still
problematic (Haller et al., 1997). Thus, in addition to removing external barriers to care it is
important to remove internal barriers to care such as ambivalence about giving up substance
use, which is common in individuals entering substance abuse treatment (Shaffer and
Simoneau, 2001). Relatedly, it has been suggested that best practices for treating pregnant
substance users include the use of a nonjudgmental and non-punitive approach as opposed to
a confrontational one (Howell et al., 1999). Motivational enhancement therapy (MET), which
seeks to reduce ambivalence about change in a non-confrontational, non-judgmental manner,
would thus seem to be an ideal treatment for reducing internal barriers to treatment in pregnant
substance users.
Several studies have found that the use of brief motivational interventions, such as motivational
interviewing (MI) or MET, significantly increases treatment utilization in substance abusing
populations (Saunders et al. 1995; Swanson et al., 1999; Martino et al., 2000; Carroll et al.,
2001; Carroll et al., 2006). One prior trial has evaluated the efficacy of MI, combined with
vouchers for goods earned for negative urine toxicology screens, for increasing treatment
retention in pregnant substance users (Jones et al., 2002; Jones et al., 2004). Based on the poor
treatment compliance of the first 31 pregnant substance users enrolled, the investigators added
a case management component in an effort to improve treatment retention for the subsequent
59 participants enrolled (Jones et al., 2004). While the participants receiving case management
attended the first treatment session at a higher rate than those without case management,
subsequent treatment retention was not significantly different between the two groups (Jones
et al., 2004). The Jones et al. (2004) study highlighted two important characteristics of pregnant
substance abusing women: as a group, they have enormous unmet psychosocial needs,
frequently including the basic needs of food and shelter and, second, retaining this population
can be extremely difficult. However, since the Jones et al. (2004) study was conducted in a
research setting in which treatment was limited to brief interventions and case management, it
is difficult to delineate any additional implications for substance abuse community treatment
programs (CTPs), which offer a wider range of treatment options. Perhaps in the context of
more comprehensive treatment services, MI or MET might be effective in increasing pregnant
substance users’ utilization of these services.
The use of brief motivational interventions in pregnant substance users is also of interest in
terms of their potential efficacy in reducing substance use. In the Jones et al. study (2002), the
subgroup of participants receiving all 4 MET sessions, compared to those not receiving all 4
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sessions, had significantly less substance use and better birth outcomes, suggesting that MET
might have some efficacy in reducing substance use. The possible efficacy of motivational
interventions in reducing substance use in pregnant women is also suggested by a pilot study
of MI in reducing alcohol consumption in a primary care sample of pregnant women
(Handmaker et al., 1999). The findings suggest that a 1-hour motivational interview, compared
with letters informing control participants of the risks of drinking during pregnancy, seemed
to significantly benefit the women who had reported drinking the most during the initial
interview. Specifically, this subgroup of women assigned to the MI condition reported
significantly lower levels of intoxication at the 2 month follow up than did comparable
participants in the control group (Handmaker et al., 1999).
The primary objective of the present trial was to evaluate the efficacy of a 3 session MET
intervention for pregnant substance users (MET-PS), compared to treatment as usual (TAU),
in increasing treatment utilization and decreasing substance use during the first month of
treatment. Evaluating the longer-term efficacy of MET-PS, relative to TAU, was an important
secondary objective. This randomized, parallel, two group trial included a 1 month active study
phase with 2 follow-up assessments completed at 1 and 3 months, respectively, following the
end of the active study phase. It was predicted that MET-PS, compared to TAU, would
significantly increase treatment utilization and decrease substance use during the first month
of treatment. In addition, it was predicted that MET-PS, compared to TAU, would significantly
increase treatment utilization and decrease substance use through the entire 4 month study
period.
2. Materials and methods
2.1 Study Overview
This study was conducted by the National Institute on Drug Abuse (NIDA) Clinical Trials
Network (CTN). The CTN was established in 1999 in response to an Institute of Medicine
report (Lamb et al. 1998) delineating the relative lack of information exchange between
substance abuse researchers and substance abuse community treatment providers, resulting in
the minimal impact of research findings on treatment practice. In CTN, substance abuse
researchers work together with treatment providers to identify promising treatment approaches,
to design clinically meaningful trials, and to implement the clinical trials in the “real world”
settings of the CTPs, utilizing the existing staff as interventionists and clinic patients as
participants. The present trial was thus conceived and designed by a team of researchers and
substance abuse treatment providers from CTPs with programs for pregnant women. One of
the important study design decisions resulting from this collaboration was the choice of the
control condition. Based on the treatment providers’ expressed interest in understanding how
MET-PS compared to their current treatment practices, as opposed to a standard control
condition, it was decided, in the interest of clinical relevance, to compare MET-PS to treatment
as usual (TAU) at the participating CTPs.
2.2 Study Sites
A total of 12 CTPs expressed interest in participating as study sites, of which the 4 sites treating
the greatest number of pregnant women in outpatient treatment were selected; one additional
site had been selected but closed for fiscal reasons prior to study initiation. Each of the four
community treatment programs randomizing participants into this study were women-specific
programs. The Horizons Program in North Carolina is a comprehensive treatment program for
substance-using women and their children. The program offers several levels of outpatient
treatment (including IOP) as well as specialized services for specific populations including a
prenatal clinic, a residential program for women and children, and a licensed childcare facility.
At the time of participation in this study, Horizons was admitting approximately 75 –100
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women per year, of which approximately 55% were pregnant. The Milagro Program in New
Mexico is a perinatal substance abuse prevention and treatment project that provides an array
of services to alcohol and other drug dependent pregnant or postpartum women and their
children. These services include high risk prenatal care, outpatient and residential substance
abuse treatment, opioid replacement therapy, nursing care management (prenatal and post
partum), delivery, inpatient care, parenting classes, and pediatric follow up. Milagro serves
approximately 150 women per year, all of whom are pregnant at time of admission.
Project Home at Midtown Community Mental Health Center in Indiana provides a home-based
outpatient treatment program with comprehensive services to pregnant and parenting women
who use substances, and to their families. Project Home includes individual, group and family
therapy as well as education that focus on perinatal substance use, parenting, vocational goals,
life skills and independent living. The program also operates a transitional housing program
for clients and their children. At the time of participation in the study, Project Home maintained
a census of approximately 60 active cases. Overall, Midtown CMHC serves approximately 90
pregnant substance using women per year across all its outpatient services, including Project
Home. Project Link at JADAC in Kentucky serves over 100 pregnant substance-using women
per year, using a case management model for treatment engagement and retention. Through
ongoing assessment and case management, Project Link clients are linked to substance abuse
treatment modalities at JADAC, including women’s IOP, substance abuse education,
detoxification, and residential substance abuse treatment. Case managers also link clients to
other community resources as appropriate.
2.3 Participants
Participants for the study were recruited from intakes to the pregnant women treatment
programs of the 4 participating CTPs. Study staff worked to increase clinic intakes by using
advertising and direct community promotions, such as networking with community
professionals and presenting at community health fairs, to promote the clinic. All participants
were given a thorough explanation of the study and signed an informed consent form that was
approved by the Institutional Review Boards of the participating sites.
Eligible participants were at least 18 years of age and pregnant (as confirmed by a pregnancy
test) and not planning to terminate the pregnancy. To be eligible, participants were required to
be identified as needing substance abuse treatment via the CTP’s usual screening procedure
and to have a living arrangement of sufficient stability to allow for outpatient treatment.
Participants were excluded from the study if they required residential or inpatient treatment
(other than detoxification), were more than 32 weeks pregnant, planned to relocate from the
area within 4 months of signing the study consent form, had pending legal charges that might
lead to incarceration (other than those requiring the participant to attend treatment), or were a
significant suicidal/homicidal risk. A total of 733 were pre-screened, 204 signed consent and
200 were randomized into the trial. Of the 533 participants excluded, 82 (15.4%) were not
pregnant, 151 (28.3%) did not need to enter substance abuse treatment, either due to not using
substances or to already being in treatment, 20 (3.8%) were under 18 years of age, 32 (6%)
were not interested in participating, 9 (1.7%) had unstable living arrangements, 10 (1.9%) had
plans to relocate within 4 months, 9 (1.7%) had pending legal charges, 110 (20.6%) self-
reported having conditions that required inpatient/residential treatment, 4 (<1%) were a
significant suicidal/ homicidal risk, 38 (7.1%) were more than 32 weeks pregnant, and 68
(12.8%) were ruled out for other reasons (e.g., planning to terminate the pregnancy, refused
treatment services, etc.).
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The study clinicians were 23 substance abuse counselors from the 4 participating CTPs. If
required by the site IRB, the clinicians signed informed consent. Clinicians were eligible to
participate if they had experience working with pregnant substance users and/or had been
trained to work with pregnant substance users, were willing to learn and implement a
manualized version of MET-PS, were willing to participate in the study as a clinician (e.g.,
willing to be randomly assigned to either the MET-PS or TAU condition, willing to have their
sessions audiotaped, etc.), and were approved by administrative/ supervisory staff as
appropriate for the study. Clinicians were excluded if they had received credentialing as a MET
trainer or had served as a MET clinician in a prior clinical trial, with the exception of the last
clinician added to the trial, who was the only staff person available to replace a MET-PS
clinician and who had received credentialing as a MET trainer. To help ensure the
comparability of the clinicians administering MET-PS and TAU, all eligible clinicians were
randomly assigned to the MET-PS or TAU condition. As a group, the clinicians were primarily
female (91.3%), racially diverse, with 52% Caucasians, 39% African Americans, and 9%
Hispanics, and had a mean age of 40 (SD=10.8). The majority of clinicians had a masters degree
(74%), with the remaining 26% having a bachelors degree. Six of the clinicians (26.1%) were
licensed or certified in social work, 4 were licensed professional counselors (17.4%), 1 clinician
was a nurse (4.3%), 1 was a marriage and family therapist (4.3%), and 1 clinician was a certified
alcohol and drug counselor (4.3%). Participants were assigned to clinicians on the basis of
availability.
2.5 Study Treatments
2.5.1 Motivational Enhancement Therapy for Pregnant Substance Users (MET-
PS)
Intervention: The MET-PS intervention is comprised of the brief motivational techniques
described by Miller and colleagues (Miller and Rollnick, 1991; Miller, 1999), modified
specifically for pregnant substance users. The MET-PS intake session began with developing
rapport through the use of open ended questions including discussion of the participant’s
feelings about her pregnancy, reflective listening, affirming the participant, and summarizing
what the participant said. In addition, the participant’s perceived pros and cons of using
substances, including possible adverse effects on the fetus, were explored. The remainder of
the session was devoted to the clinic’s usual assessment and intake procedures. The second
session was devoted to reviewing the participant’s individualized personal feedback report
concerning the consequences of substance use for both the participant and her pregnancy and
the degree to which she was engaging in activities to promote a healthy pregnancy. The third
session was devoted to developing a change plan for participants who expressed a readiness
to change and strengthening commitment to change in participants who were not yet ready to
change. These 3 sessions replaced the intake session and the first 2 individual treatment sessions
typically offered by the CTP. The first MET-PS session was approximately 1.5 to 2 hours in
length while the other 2 sessions were approximately an hour in length. Participants in the
MET-PS condition were encouraged to participate in the other treatment services typically
offered at the CTP (e.g., group treatment, case management, etc.).
Training: Clinicians randomly assigned to MET-PS completed 20 hours of training with a
MET Expert that included a lecture format as well as role playing exercises involving scenarios
with pregnant substance users. Three MET Experts provided training during the course of the
trial; two were members of the Motivational Interviewing Network of Trainers (MINT), while
the third was Dr. Nancy Handmaker, the Principal Investigator for the pilot study of MI in
reducing alcohol consumption in pregnant women (Handmaker et al., 1999). Following
training, each MET-PS clinician completed at least 1 training case, working with a pregnant
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substance user from the CTP. The training cases were supervised by a protocol MET-PS
supervisor via ratings of the audiotaped sessions for clinician adherence and competence,
utilizing a system used in previous multi-site clinical trials (Carroll et al., 2006). The inter-
rater reliability of the 2 MET-PS supervisors was evaluated for a randomly selected sample of
ten tapes. The intraclass correlation coefficients (ICCs), calculated according to Shrout and
Fleiss (1979), revealed that the supervisors evidenced an excellent level of inter-rater reliability
for the MET adherence (.97) and skill (.90) scales. Clinicians receiving ratings of at least
“average” on half of the MET items for both adherence and skill were then eligible to be
assigned study participants. Otherwise, the clinician completed additional training cases and
supervision until meeting this criterion.
Treatment Integrity: Clinician adherence and competence was monitored via the ongoing
review of randomly selected audiotaped sessions by the protocol MET-PS supervisors; 62%
of the sessions were reviewed. Any clinician identified as performing below the set standards
(i.e., at least “average” on half of the MET items for both adherence and skill) was given
additional training and more intense supervision until he or she met or exceeded standards.
2.5.2 Treatment As Usual—Participants assigned to TAU were offered the treatment
typically provided at the CTP with the constraint that they receive at least 3 individual sessions
with a clinician, including the intake session. For 3 of the sites, this did not require any
modification to their normal program. The fourth site, which has a primary focus on case
management and typically offers individual counseling only on a monthly basis, modified its
program to include 2 weekly individual counseling sessions in addition to the standard intake.
All study participants were offered the other services typically provided by the CTP (e.g., group
treatment, additional individual treatment, case management, etc.). The 3 individual sessions
were audiotaped to allow for an evaluation of the discriminability between TAU and MET-PS
sessions. As in the MET-PS intervention, the first TAU session was approximately 1.5 to 2
hours in length while the other 2 sessions were approximately an hour in length.
2.5.3 Treatment Discriminability—In order to test the efficacy of MET-PS compared to
TAU, it must be established that the MET-PS and TAU sessions could be distinguished from
one another. This check on the discriminability of the MET-PS/TAU sessions was completed
by having a randomly selected sample of tapes reviewed by 3 raters who were blind to clinician
treatment assignment and who had no other involvement in the study except to rate the sessions.
The current study utilized the adherence and competence instruments utilized in previous multi-
site clinical trials (Carroll et al., 2006). Specifically, 10 items each were used to assess the
clinician’s utilization of MET (e.g., avoiding confrontation, asking open-ended questions,
reflective listening) general substance abuse counseling (e.g., substance use assessment,
discussion of pregnancy and substance use, treatment planning), and strategies inconsistent
with MET (Anti-MET; e.g., confrontation of denial, asserting the authority of the therapist).
Each item was rated for adherence (1: not present in the session to 7: extensively) and skill (1:
very poor to 7: excellent).
Following training, including feedback on rated tapes, the inter-rater reliability of the 3
independent raters was evaluated for a randomly selected sample of 6 tapes. The intraclass
correlation coefficients (ICCs), calculated according to Shrout and Fleiss (1979), revealed that
the raters evidenced a good level of inter-rater reliability for the adherence scales for MET (.
83), General Counseling (.91), and Anti-MET (.81) and for the skill scales for MET (.86),
General Counseling (.89), and Anti-MET (.82). A total of 434 sessions (228 TAU and 206
MET-PS) were completed during the study, of which 167 were rated by the independent raters.
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The primary outcome measure was treatment utilization defined as the ratio of the number of
outpatient (including intensive outpatient) treatment hours attended to the number of hours
scheduled. Secondary outcome measures of treatment utilization included the number of weeks
in which at least 1 treatment session was attended and the number of weeks until treatment
dropout, defined as failure to attend any treatment provided by the CTP for 3 consecutive
weeks, while the participant was still pregnant; the 3-week time-frame was selected a-priori
based on a consensus among the substance abuse treatment providers on the study design team
regarding how they would define a “drop out” in their treatment programs. The 3 measures of
treatment utilization were based on clinic records of treatment attendance.
The secondary outcome measures of substance use included self-report of substance use (i.e.,
alcohol and illicit drugs) and qualitative urine toxicology results. Urine samples were collected
and tested for opiates, cocaine, methamphetamines, benzodiazepines, and marijuana at
screening, weekly during the active study phase, and at the 2 follow-up visits using the OnTrak
TesTcup®. The Substance Use Calendar, a self-report assessment of the participant’s use of
substances for each day of the study, was completed at each research visit using the Timeline
Follow-Back procedure (Sobell and Sobell, 1992; Fals-Stewart, 2000). The University of
Rhode Island Change Assessment (URICA) (DiClemente & Hughes, 1990) was used to assess
the participants’ motivation to change their substance use behavior. The URICA was completed
at baseline and at the end of the active study phase. Four scales are derived from the URICA:
Pre-contemplation, Contemplation, Action and Maintenance; a readiness score which
combines these scales (Pantalon et al., 2002) was used for the present study.
2.7 Procedures
Pregnant women identified by CTP clinical staff as needing substance abuse treatment and
who expressed a willingness to learn more about the study were referred to the research assistant
(RA). After signing the Informed Consent Form, the study candidate completed screening and
baseline assessments. Ineligible individuals continued into the CTP’s standard intake
assessment and treatment program. Eligible participants were assigned to MET-PS or TAU
via urn randomization to balance on 3 dichotomous variables: pressure to attend treatment,
self-report of drug and alcohol use, and need for methadone maintenance. Pressure to attend
treatment was defined as having jail, the removal of a child (or children), or the removal of
housing as the consequence of not attending treatment. The self-report of use variable was
operationalized as the number of days in the past 28 that the participant reported using alcohol
and/or drugs (<10 or ≥10 days of use in the last 28 days). Need for methadone maintenance
was determined by the participant’s self-report of substance use and the treatment referral
practices followed at the CTP.
The active study phase was 4 weeks in duration. During this time, participants in both treatment
conditions were offered at least 3 individual sessions with a clinician. An attempt was made
to have the study participant attend the initial treatment session (MET-PS or TAU) immediately
following randomization but, in practice, the initial session typically occurred within the first
week of randomization. There was a 28-day time frame, starting from randomization, for the
participant to receive the 3 MET-PS/TAU sessions with the constraint that no more than 2
sessions occurred in a single week. Participants in both conditions were encouraged to
participate in the other treatment services offered by the CTP (e.g., group treatment, case
management, etc.) During the first month of treatment, participants were scheduled to meet
with the RA on a weekly basis. In addition, the participants were scheduled to meet with the
RA at the 2 and 4 month post-randomization follow-up visits. Study participants received $30
in retail scrip or vouchers for each of the 5 research visits that were relatively long (i.e., the 2
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baseline visits, the end of active phase visit, and the 2 follow-up visits) and $25 for each of 3
research visits that were relatively brief.
2.8 Data Analysis
Per the study statistical analysis plan, the primary outcome measure, the ratio of attended to
scheduled treatment hours during the first month of treatment, was analyzed using a Cox
proportional hazards model with the log of the number of scheduled hours and the type of
patient (intensive outpatient or outpatient) as covariates. The present study was powered to
detect differences between the treatment groups when the data were pooled across sites, and,
thus, the protocol-specified analyses did not include an evaluation of site by treatment
interaction effects; however, analyses evaluating such effects were included as exploratory
analyses; specifically, the three sites with sufficient sample size were included in these
analyses.
In addition, the statistical analysis plan did not specify the inclusion of treatment group baseline
differences as possible covariates in the statistical models. There were a number of significant
baseline differences between the MET-PS and TAU groups (see section 3.1). The baseline
differences that were deemed most likely to be related to treatment outcomes were: 1. the
greater proportion of participants with cocaine as the primary drug of choice in the MET-PS
group; 2. the greater proportion of participants with marijuana as the primary drug of choice
in the TAU group; 3. the greater proportion of participants in the TAU group with pressure to
attend treatment. In addition, since a meta-analysis revealed that the effect sizes of MI were
larger in ethnic minorities (Hettema et al., 2005), we also evaluated the importance of the group
baseline difference of significantly more minority participants in the MET-PS group. The
importance of these baseline differences was tested for each outcome measure by introducing
the covariate into the model as the lone covariate and retaining those covariates with a p value
less than .10 in the final analysis of the outcome variable.
Several statistical analyses were utilized for the secondary outcome measures, depending upon
the nature of the data. Secondary analyses involving repeated measures data were analyzed
using Generalized Estimating Equations (GEE) first with a regression including week as an
effect, and if no week effects were found, a second regression testing for a treatment effect was
completed without week in the model. In addition, for the repeated measures data, two sets of
analyses were conducted; the first included data from the first month of treatment only while
the second included the data from randomization through 4 month follow-up. Non-longitudinal
binomial data were analyzed with logistic regression using a quasi-likelihood approach to
accommodate possible over-dispersion. The survival analysis of time to drop out while
pregnant was completed with a Cox proportional hazards model in which data points with a
value of 106 or more days were censored as were the data from 6 participants who withdrew
consent. All analyses were conducted for both the ITT sample (i.e., all 200 randomized
participants) as well as for the evaluable sample, which was comprised of the 171 participants
who received at least 1 MET-PS or TAU session; results for the evaluable sample are reported
where they differed from those of the ITT sample.
3. Results
3.1 Sample Characteristics
The sample characteristics by site and by treatment group are provided in Table 1. The
participants were, on average, 26 years of age and 20 weeks pregnant at the time of
randomization. The majority of study participants were unmarried, were unemployed and had,
on average, a high school education. As can be seen in Table 1, the sample was fairly diverse
in terms of race and ethnicity. There were significant site differences on many participant
Winhusen et al. Page 8













characteristics including age, race/ethnicity, marital status, number of weeks pregnant at time
of randomization, primary drug of choice, days of substance use, need for methadone
maintenance, and pressure to attend treatment. This suggests that the study was successful in
including a diverse set of sites. There were a number of significant baseline differences between
the MET-PS and TAU groups, including significantly older participants in the MET-PS group,
significantly more minority participants in the MET-PS group, significantly more years of
education in the MET-PS group, significantly more participants with cocaine as a primary drug
of choice in the MET-PS group, and significantly more participants with marijuana as a primary
drug of choice in the TAU group. In addition, there was a trend (p=.07) for more participants
with pressure to attend treatment in the TAU group.
3.2 Study Retention
A total of 162 study participants (81%) completed the 4 week active study phase. Study
completion rates did not differ significantly between the MET-PS (79.4%) and TAU (82.7%)
treatment groups (X2=0.34, df=1, p>.05). Fifty-five percent of early terminations were
participants who failed to attend the clinic visits and could not be reached, with no significant
difference between the MET-PS (10/102, 10%) and TAU (11/98, 11%) groups (X2=0.11, df=1,
p>.05). Eighteen percent of early terminations were participants who reported that they were
unable to attend visits due to practical problems (e.g., issues with transportation, childcare,
etc.), with no significant difference between the MET-PS (3/102, 3%) and TAU (4/98, 4%)
groups (X2=0.19, df=1, p>.05). Sixteen percent of early terminations were participants who
withdrew consent, with no significant difference between the MET-PS (5/102, 5%) and TAU
(1/98, 1%) groups (X2=2.59, df=1, p>.05). Another 8% of terminations resulted from
participants being incarcerated, with no significant difference between the MET-PS (3/102,
3%) and TAU (0/98, 0%) groups (X2=2.93, df=1, p>.05). Finally, 1 TAU participant reported
that she did not need treatment and so discontinued study participation.
3.3 Treatment Fidelity and Discriminability
If MET-PS and TAU are distinguishable, and if MET-PS were implemented correctly, one
would expect the MET-PS, compared to TAU, sessions to receive significantly higher ratings
on the MET adherence and skill scales and to receive significantly lower ratings on the Anti-
MET adherence and skill scales. Analysis of variance (ANOVA) was conducted for the
adherence and skill ratings for the MET and General Counseling scales, with the natural log
used for the adherence ratings on General Counseling to make the data more normal. A Cox
model was used for the adherence and skill ratings on the Anti-MET scale due to the extreme
non-normality of the data. These analyses revealed that the MET-PS, compared to the TAU,
sessions were rated significantly higher on the MET adherence (F=59.13, df=1, p<.001) and
skill (F= 37.94, df=1, p<.001) scales. The analysis also revealed that the TAU, compared to
the MET-PS, sessions were rated significantly higher on the Anti-MET scales for both the
adherence (F=25.08, df=1, p<.001) and skill (F=24.79, df=1, p<.001) scales, suggesting that
elements antithetical to MET were less likely to occur in the MET-PS compared to the TAU
sessions. A significant site by treatment effect was found for Anti-MET skill; post hoc tests
revealed that this significant effect suggests that, overall, MET-PS clinicians had less skill on
the Anti-MET scale compared to TAU clinicians but that this difference was diminished at Site
B. Somewhat surprisingly, the TAU sessions, compared to the MET-PS sessions, were rated
more highly on the adherence (F=11.64, df=1, p<.001) and skill (F=9.89, df=1, p<.01) scales
for general counseling.
3.4 Treatment Utilization
3.4.1 Ratio of attended to scheduled hours—The primary outcome analysis, which did
not include baseline covariates or site effects, revealed no significant Treatment effect
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(X2=0.52, df=1, p>.05) on the proportion of scheduled hours attended during the first month
of treatment. As can be seen in Table 2, the participants, on average, attended approximately
62% of their scheduled treatment hours, which translates into an average of 9.0 hours
(SD=11.4) attended for TAU and 6.2 hours (SD=10.9) for the MET-PS participants. The
exploratory analysis, which included baseline covariates (see section 2.8) and site in the model,
revealed no significant Treatment effects, including Site × Treatment interaction effects.
3.4.2 Days until Treatment Drop Out—The analysis of the number of days until drop-out
while the participants were still pregnant revealed a non-significant Treatment effect (X2=0.22,
df=1, p>.05) and a significant Site × Treatment interaction effect (X2=10.15, df=2, p<.05).
Contrast analyses revealed that Site C, at which the MET-PS participants dropped out of
treatment more quickly than the TAU participants, differed significantly from Sites A
(X2=5.20, df=1, p<.05) and B (X2=9.51, df=1, p<.01), at which this effect was not seen. An
analysis of each site separately revealed no significant Treatment effect for either Sites A
(X2=0.53, df=1, p>.05) or B (X2=2.21, df=1, p>.05) but did reveal a significant Treatment
effect for Site C (X2=6.6, df=1, p<.05), suggesting that MET-PS participants dropped out of
treatment significantly earlier at this site compared to TAU participants. The differential in
days to drop-out between MET-PS and TAU, as a function of site, can be seen in Table 2.
3.4.3 Number of Weeks in which treatment attended—A secondary measure of
treatment utilization was the number of weeks in which at least 1 treatment session was attended
during the first month of treatment and during the entire 4-month study period. The analyses
revealed no significant Treatment effects, including Site by Treatment interaction effects, for
the first month of treatment or for the entire 4 month treatment period. As can be seen in Table
2, the MET-PS participants attended an average of 2.4 weeks of treatment during the first month
of treatment while the TAU participants attended an average of 2.7 weeks. During the 3 month
follow-up period, the MET-PS participants attended an average of 5.0 weeks of treatment
compared to an average of 6.0 weeks by TAU participants.
3.5 Substance Use
3.5.1 Urine Toxicology Results—The overall proportion of positive urine toxicology
screens as a function of study phase, treatment group, and site can be seen in Table 3. The
analysis of the urine toxicology results revealed a significant Treatment × Week × Site effect
for the first month of treatment (X2=7.65, df=2, p<.05) and a marginally significant Treatment
× Week × Site effect for the entire 4-month period (X2=5.50, df=2, p=0.064); contrasts revealed
that this effect represented a significant difference between Sites A and C for both the first
month of treatment (X2=6.11, df=1, p<.05) and the entire 4-month period (X2=5.43, df=1, p<.
05), with MET-PS participants evidencing a greater decrease in the number of positive urine
toxicology samples compared to TAU at Site A and the reverse true at site C. When this analysis
was repeated for the evaluable sample, the results revealed an additional site effect: for the first
month of treatment, Site A was significantly different than site B (X2=3.97, df=1, p<.05), with
MET-PS participants evidencing a greater decrease in the number of positive urine toxicology
samples compared to TAU at Site A, an effect not seen at site B at which MET-PS and TAU
were more equivalent.
Within site analyses revealed no significant Treatment effects for either Sites A or B for either
the first month of treatment or the entire 4 month study period. For Site C, there was a
marginally significant Treatment by Week effect for the first month of treatment (Z=1.92,
p=0.054) in the ITT sample, which was significant in the evaluable sample (Z=2.14, p<.03).
For the entire 4 month study period, the analysis for Site C revealed a significant Treatment
by Week effect (Z=2.28, p<.05), suggesting that MET-PS, compared to TAU, participants had
a higher proportion of positive urine toxicology results.
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3.5.2 Self-report of drug and alcohol use—Analysis of the days of drug or alcohol use
during the first month of treatment found no significant Treatment (Z=1.19, p>.05), Treatment
× Week (Z=0.56, p>.05), or Site × Treatment × Week (X2=2.15, df=2, p>.05) effects but did
reveal a significant Week effect (Z=−2.40, p<.05). Review of Figure 1 suggests that both groups
evidenced a significant decrease in drug/alcohol use during the first month of treatment. To
determine whether the significant Week effect could be explained by the drop-out of the non-
completers, we re-ran the analysis including completion status as a covariate and the results
were equivalent (i.e., the Week effect was Z=−2.23, p<.05). Analysis of the days of drug or
alcohol use during the entire 4-month period revealed no significant Treatment (Z=1.11, p>.
05), Treatment × Week (Z=−0.95, p>.05), Week (Z=0.02, p>.05), or Site × Treatment × Week
(X2=0.68, df=2, p>.05) effects.
3.6 Readiness to Change
Analysis of the URICA-derived Readiness score revealed a significant treatment effect
(X2=5.77, df=1, p<.05). The mean change from baseline to end of treatment was −3.7
(SD=13.7) for TAU compared with 0.3 (SD=9.8) for MET-PS, indicating that the TAU group
reported less readiness to change at the end of treatment, compared to the baseline, while the
MET-PS group’s level of readiness did not change.
3.7 Minority Analyses
In accordance with NIH guidelines, we completed analyses to determine whether treatment
was differentially effective for individuals from a minority group. Our sample size only allowed
for analyses evaluating minority vs. non-minority status as opposed to analyses for particular
minority groups. The minority analyses followed the same data analytic strategies as those
outlined in section 2.8 with the exception that each model included Minority (minority vs. non-
minority) and Minority by Treatment effects in the model.
3.7.1 Treatment Utilization—A Chi-square analysis revealed that minority, compared to
non-minority, participants were significantly less likely to have received at least 1 MET-PS/
TAU session and, thus, to be in the evaluable sample (X2=10.4, df=1, p<.01). Specifically
78.8% of minority participants included in the ITT sample were also in the evaluable sample
compared to 95.1% of non-minority participants. This effect was largely due to Site C, which
had 62% of minority participants in the evaluable sample compared to 100% of non-minority
participants (X2=5.47, df=1, p<.05). Site B also had fewer minority (83%) compared to non-
minority (94%) participants in the evaluable sample but this was not statistically significant
(X2=2.08, df=1, p>.05). At Site A, 97% and 96% of non-minorities and minorities,
respectively, were in the evaluable sample.
Analysis of the primary outcome measure, ratio of attended to scheduled hours, revealed no
significant Minority or Minority by Treatment effects. The number of days until drop out while
pregnant also revealed no significant Minority or Minority by Treatment effects. However,
number of weeks in which treatment was attended revealed a significant Minority effect
(X2=8.64, df=1, p<.01) when site was included in the model, with minority individuals
attending significantly fewer weeks of treatment during the first 28 days of treatment; this
effect was not significant when the entire 4 month period was included (X2=1.03, df=1, p>.
05).
3.7.2 Substance Use—Analysis of the urine toxicology data revealed no significant
Minority or Minority × Treatment effects. Analysis of self-report of alcohol or illicit drug use
during the first month of treatment revealed no significant Minority or Minority × Treatment
effects while self-report for the entire 4-month period revealed a significant Minority effect
(Z=−2.08, p<.05) and a marginally significant Minority × Treatment effect (Z=1.96, p=0.0504)
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in ITT, which was significant in the evaluable sample (Z=2.24, p=.0253). As can be seen in
Figure 2, which provides the data from the evaluable sample, minority participants in MET-
PS reported a greater decrease in substance use compared to minority participants in the TAU
condition.
3.7.3 Readiness to Change—Analysis of the URICA readiness data revealed a significant
Minority by Treatment effect (X2=5.99, df=1, p<.05). Review of the graph (data not shown)
suggests that this effect was primarily due to non-minority TAU, compared to MET-PS,
participants reporting less readiness to change at the end of treatment, compared to baseline,
while this effect was not evident for minority participants.
4. Discussion
This randomized controlled trial of MET for pregnant substance users revealed no evidence
that MET-PS was more effective than TAU in increasing treatment utilization or decreasing
substance use in the study sample as a whole. The failure to find an effect for MET-PS on
treatment utilization is consistent with a study conducted by Jones et al. (2004) in which MI
plus behavioral incentives had minimal effect in increasing treatment retention in substance
using pregnant women. The failure to find an effect on substance use is inconsistent with the
findings from a pilot study with pregnant alcohol drinkers which found that a 1 hour MI session,
compared to letters informing participants of the risk of alcohol use during pregnancy,
significantly lowered self-reported levels of intoxication in the subgroup of women who were
using alcohol most heavily at baseline (Handmaker et al., 1999). There is a growing literature
to suggest that the benefits of MET for primary drug abusers in substance abuse treatment
might be more inconsistently observed compared to the benefits of MET for primary alcohol
abusers (Ball et al., 2007). While the Handmaker et al. (1999) study included all alcohol users,
the present trial included only 21 participants (i.e., 10.5% of the study sample) who reported
alcohol as the primary drug of choice; this difference in the two study samples could account
for the differences in the study findings. Moreover, the control condition included in the present
trial was much more intensive than the control utilized by Handmaker et al. (1999), which
could also account for the discrepant findings.
Alternatively, the failure to find an effect for MET-PS in the sample as a whole might have
stemmed from several other possible causes. First, the present study was conducted in
community treatment programs with clinic staff serving as the interventionists, which raises
the question of whether the clinicians were able to master the MET-PS intervention to the
extent to which MET-PS sessions were discriminable from TAU sessions. An analysis of the
independent tape ratings revealed that the sessions were, indeed, discriminable, with the TAU
sessions rated significantly higher on the use of techniques antithetical to MET and the MET-
PS sessions rated significantly higher on the use of MET techniques. In addition, the finding
that the MET-PS participants did not experience the decrease in readiness to change evidenced
by the TAU participants suggests that at least one of the therapeutic effects of MET-PS,
promoting readiness to change, was operational. Another possible explanation for the lack of
a MET-PS effect is the fact that we modified the MET manual used in an earlier MET trial for
use with pregnant substance users. This included the addition of discussions of the participant’s
feelings about her pregnancy, the provision of information about how substance use impacts
pregnancy outcomes, and information about the degree to which the participant was engaging
in healthy pregnancy behaviors (e.g., exercise, proper diet, etc.) as part of the personal feedback
report. The modified content might have made the MET intervention less effective. However,
research suggests that adherence to the basic principles of MET (e.g., being non-judgmental,
asking open-ended questions, reflective listening etc.) is more important than particular content
in improving patient outcome (Moyers et al., 2005) and so this is unlikely to explain the lack
of effect.
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The lack of a MET-PS effect might also have been due to a difference between the relative
counseling skills of the MET-PS and TAU clinicians. Specifically, an analysis of the
independent tape ratings revealed that the TAU sessions, compared to the MET-PS sessions,
were rated higher for both adherence and skill for items assessing general counseling
techniques. Finally, it is possible that MET-PS is simply not more effective than treatment as
usual (TAU) in increasing treatment utilization and decreasing substance use in pregnant
substance users. It should be noted that both the MET-PS and TAU participants reported
significant decreases in alcohol/drug use during the first month of treatment. This suggests that
the treatment as usual offered by the participating sites in this study was effective in decreasing
substance use; MET-PS might not have been able to evidence efficacy beyond that evidenced
by TAU. Still, it is important to note that TAU, as studied, likely differs from TAU as normally
conducted in community treatment programs. First, one of the sites participating in this trial
actually modified its normal treatment to include 2 weekly individual counseling sessions that
normally would not have been provided. Second, the assessments required for a research study,
as well as the additional attention and follow-up that both the clinic and study staff devoted to
the study participants, represent an enhancement of TAU that might have increased its efficacy.
The study results did reveal several significant Site by Treatment interaction effects but, since
this trial was not powered to compare MET-PS to TAU within site, it is difficult to determine
the importance of the Site by Treatment interactions observed. In addition, 3 sites had a
sufficient sample size to be included in the analyses of site effects with one site typically
revealing a trend towards better outcomes for MET-PS, one with better outcomes for TAU,
and one varying between trends toward better outcomes for MET-PS or TAU depending upon
the outcome variable. Given this pattern of results, it is difficult to speculate about what site
characteristics, if any, might have contributed to the results observed. The finding of site effects
is consistent with a CTN multisite study of MET, which also found evidence of site effects
(Ball et al., 2007).
An evaluation of the impact of minority status on outcome revealed that minority participants
were less likely to receive an initial MET-PS/TAU session and attended fewer weeks of
treatment during the initial month of treatment, compared to non-minorities. This finding,
which suggests that minority pregnant substance users might be particularly susceptible to
being lost early in treatment, is consistent with that of a trial with cocaine dependent individuals,
which found that African-American participants were more likely to drop out after the intake
visit compared to Caucasians (Siqueland et al., 2002) and with a retrospective chart review of
women in treatment finding that African American women were more likely to drop out of
treatment (Scott-Lennox et al., 2000). The minority analyses also revealed a significant
Minority by Treatment interaction effect for self-report of alcohol/drug use, with minority
participants in MET-PS reporting a greater decrease in use compared to minority participants
in the TAU group. This finding is consistent with the results of a meta-analysis of MI studies
which found larger effect sizes for MI in ethnic minority populations (Hettema et al., 2005).
If the present finding is replicated in a future trial it might be of interest for culturally-based
treatment approaches for pregnant substance users.
The present study had several strengths, including the use of a randomized controlled study
design, which is the gold standard for clinical trials. In addition, this study included an
unusually large number of randomized participants for the pregnant substance using population
and, to our knowledge, is the largest randomized clinical trial with this population to date.
Third, this study was conducted in the “real world” settings of substance abuse community
treatment programs in which the clinic patients were the study participants and clinic staff
members were the clinicians, and, thus, the results of this trial should be generalizable to other
community treatment programs. In addition, the check on treatment discriminability suggests
that the clinic staff randomized to MET-PS were able to implement MET-PS to the degree that
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it was readily and significantly discriminable from TAU. The present study also had several
limitations. First, the MET-PS and TAU groups were not balanced on several potentially
important baseline characteristics. This might have been due to problems with the urn
randomization programs used at the sites, although a check on program functioning during the
course of the trial indicated that the programs were operating within expected parameters. It
might have been that our attempt to balance on 3 factors resulted in an imbalance on other
factors. While we attempted to correct for the imbalances statistically by including the variables
as covariates, the imbalance might have impacted the results in a mannerthat could not be
accounted for statistically. A second limitation is that, despite attempts to have participants
receive their first session of MET-PS/TAU as soon as possible, only 85.5% of participants
received at least 1 MET-PS or TAU session.
In conclusion, the results of this trial suggest that MET for pregnant substance users was not
more effective than TAU in increasing treatment utilization or decreasing substance use in the
study sample as a whole. There was some evidence that the effect of MET-PS did vary between
sites, but, given the relatively small sample sizes within sites and the overall small number of
sites, it is difficult to speculate as to the import of these findings. Finally, there was some
indication that MET-PS might have been more effective than TAU in decreasing self-reported
use of alcohol and illicit drugs in minority, compared to non-minority, participants; this finding
would need to be replicated in order to establish its importance.
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Mean proportion of alcohol or illicit drug use days as a function of treatment group and study
week.
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Mean proportion of alcohol or illicit drug use days as a function of minority status, treatment
group, and study week
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